ASX:RNO Rhinomed (RNO) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free RNO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume452,773 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.01%Price TargetN/A Stock AnalysisStock Analysis Get Rhinomed alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About RhinomedRhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him RNO Stock News HeadlinesNovember 10, 2023 | finance.yahoo.comShareholders Will Probably Hold Off On Increasing Rhinomed Limited's (ASX:RNO) CEO Compensation For The Time BeingOctober 30, 2023 | finance.yahoo.comInsider Buyers Lose AU$435k As Rhinomed Sheds AU$1.4mApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.October 12, 2023 | msn.comWeed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in AustraliaMay 23, 2023 | finance.yahoo.comMeredith George Bought 6.7% More Shares In Rhinomed \April 1, 2023 | finance.yahoo.comMeredith George Just Bought 8.2% More Shares In Rhinomed Limited (ASX:RNO)March 3, 2023 | finance.yahoo.comRhinomed First Half 2023 Earnings: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)December 30, 2022 | finance.yahoo.comRhinomed Limited (ASX:RNO) insiders placed bullish bets worth AU$2.2m in the last 12 monthsApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.September 30, 2022 | finance.yahoo.comWe're Hopeful That Rhinomed (ASX:RNO) Will Use Its Cash WiselyApril 27, 2022 | finance.yahoo.comTrade Alert: The Non-Executive Director Of Rhinomed Limited (ASX:RNO), John McBain, Has Just Spent AU$925k Buying 10% More SharesApril 11, 2022 | finance.yahoo.comRhinomed (ASX:RNO) jumps 20% this week, taking one-year gains to 113%December 3, 2021 | finance.yahoo.comRhinomed Limited (ASX:RNO) insiders placed bullish bets worth AU$802k in the last 12 monthsSeptember 7, 2021 | finance.yahoo.comEthics Approval Granted for Clinical Trial of World's First Nasal Swab Designed Specifically for ChildrenAugust 25, 2021 | finance.yahoo.comWe're Not Very Worried About Rhinomed's (ASX:RNO) Cash Burn RateSee More Headlines Receive RNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhinomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2019Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:RNO CUSIPN/A CIKN/A Webwww.rhinomed.com.au Phone+61-3-84160900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,910,000.00 Net Margins-135.49% Pretax MarginN/A Return on Equity-388.13% Return on Assets-101.64% Debt Debt-to-Equity Ratio2,261.76 Current Ratio0.27 Quick Ratio1.28 Sales & Book Value Annual Sales$8.05 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.48 Book ValueA($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares286,780,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.88 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Michael JohnsonCEO, MD & Executive DirectorMr. Sean SlatteryCFO & Company SecretaryKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersMichael JohnsonBought 130,165 shares on 2/2/2024Total: $3,384.29 ($0.03/share)John McBainBought 100,000 shares on 9/5/2023Total: $7,000.00 ($0.07/share)Michael JohnsonBought 55,555 shares on 5/3/2023Total: $3,999.96 ($0.07/share) RNO Stock Analysis - Frequently Asked Questions How were Rhinomed's earnings last quarter? Rhinomed Limited (ASX:RNO) issued its earnings results on Thursday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter. Rhinomed had a negative trailing twelve-month return on equity of 388.13% and a negative net margin of 135.49%. This page (ASX:RNO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhinomed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
